

IN THE CLAIMS

1. (currently amended) A combination useful for simultaneous, sequential or separate administration in anticancer or antiviral therapy, comprising calcium, injectable magnesium and an active ingredient which releases oxalate during its metabolism, wherein part of the calcium is in injectable form and the other part is in oral form.

2. (cancelled)

3. (currently amended) The combination of claims 1 ~~or~~ 2, wherein said active ingredient is oxaliplatin.

4. (currently amended) The combination of claims 1 ~~to~~ 3, wherein the calcium is in-present as a gluconate, chloride, bromogalactogluconate, gluconolactate or carbonate form-salt, and the magnesium is in-present as a sulfate or pidolate formsalt.

5. (previously presented) The combination of claim 4, wherein part of the calcium is in injectable form and the other part is in oral form, and wherein said injectable calcium is present in a concentration between 8 and 20 mg/ml, and wherein said injectable magnesium is present in a concentration between 10 and 20 mg/ml, the concentrations being expressed as calcium ions.

6. (currently amended) A method of preventing or treating neurotoxicity caused by the administration of a product that releases oxalate during its metabolism, comprising administering to a patient that has received, is receiving, or will receive a product that releases oxalate during its metabolism a combination of calcium and magnesium effective to prevent or treat the neurotoxicity, wherein part of the calcium is administered to the patient in injectable form and the other part is administered in oral form.

7. (cancelled)

8. (previously presented) The method of claim 6, wherein the product which releases oxalate is oxaliplatin.

9. (currently amended) The method of claim 76, wherein the calcium and magnesium are administered to the patient prior to, after, or both prior to and after administration of the product that releases oxalate during its metabolism.

10. (currently amended) The method of claim 76, wherein the calcium and magnesium are administered to the patient simultaneously with administration of the product that releases oxalate during its metabolism.

11. (currently amended) The method of claim 76, wherein said calcium and magnesium are administered separately.

12. (previously presented) The combination of claim 5, wherein the concentration of said injectable magnesium is 15 mg/ml.